Perioperative chemotherapy for non-small-cell lung carcinoma: problems and solutions
https://doi.org/10.18027/2224-5057-2015-3-18-23
Abstract
Lung cancer (LC) is the most frequent malignant tumor and leading cause of death among oncological diseases worldwide. Mortality due to lung cancer is comparable with cumulative mortality due to prostate, colon and pancreatic cancer [10]. About 85% cases of LC are non-small-cell lung carcinoma (NSCLC). Although the operation is considered as the optimal treatment, only 25–30% cases of these tumors are potentially resectable. Five-year survival after surgical treatment for stage IA of NSCLC is 73% and for stage IIIA — is 25% [3]. Only 31–40% of patients who need adjuvant treatment receive it [5].
About the Author
D. D. SAKAEVA
Republican Clinical Oncological Health Center of Republic of Bashkortostan Ministry of Health
Russian Federation
Russian Federation
Doctor of Medical Sciences, Deputy Chief Physician in chemotherapy
References
1. Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada.J Clin Oncol. 2012 May 20;30(15):1813–21. Epub 2012 Apr 23.
2. Ardizzoni A., Tiseo M., Boni L. et al. CISCA (cisplatin vs. carboplatin) metaanalysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) // J. Clin. Oncol. — 2006. — Vol.24. — P. 366s.
3. Besse B., Le Chevalier T. Developments in the treatment of early NSCLC: when to use chemotherapy//Annals of Oncology. —2012–23 –V 23(10). — p.52–59.
4. Booth C. M., Shepherd F. A., Peng Y. et al. Adoption of adjuvant chemotherapy for non’small cell lung cancer: a population based outcomes study // J. Clin. Oncol. — 2010. — Vol.28(15s): part I, abstract 7018.
5. Bray FI, Weiderpass E. Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970–2007 // Int. J. Cancer. — 2009. — Vol.126. — P. 1454–1466.
6. Burdett S, Stewart La, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 2006;1:611–621.
7. Capeletti M., Wang X. F., Gu L. et al. Impact of KRAS mutation on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB9633 // Proc. ASCO. — 2010, J. Clin. Oncol. — 2010. —Vol.28(15s): part I, abstract 7008.
8. Gilligan D, Nicolson M, Smith I et al Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVaLT 2/ EORTC08012 multicentre randomised trial and update of systematic review. Lancet2007;369:1929–1937.
9. Imyanitov E. N., Moiseyenko V. M. Molecular_based choice of cancer therapy: realities and expectations // Clin. Chim.Acta. — 2007 (Apr). — Vol.379(1–2). — P. 1–13.
10. Jemal A., Bray F., Center M. M. et al. Global cancer statistics // J. CA Cancer Clin. — 2011. — Vol.61. — P. 69–90.
11. Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non–Small-Cell Lung Cancer J Clin Oncol. 2012;30(2):172–178.
12. Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small cell lung cancer [published online ahead of print November 28, 2011]. J Clin Oncol. 2012;30(2):172–178.
13. Song Wa, Zhou NK, Wang W, et al.Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. J Thorac Oncol 2010;5:510–516.
14. Westeel V., Milleron B. J., Quoix E. A. et al. Long’term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer // Proc. ASCO. — 2010, J. Clin. Oncol. — 2010. — Vol.28(15s): part I, abstract 7003.
15. Westeel V, Quoix E, Puyraveau M, Lavole A, Braun D, Laporte S, et al. A randomised trial comparing preoperative to perioperative chemotherapy in earlystage non-small-cell lung cancer (IFCT 0002 trial). Eur J Cancer. 2013;49(12):2654–2664.
16. Winton T., Livingston R., Johnson D. et al. Vinorelbine plus cisplatin vs.observation in resected non-small cell lung cancer // N. Engl. J. Med. — 2005. — Vol.352. — P. 2589–2597.
17. Zojwalla N. J., Raftopoulos H., Gralla R. Are cisplatin and carboplatin equivalent in the treatment of nonsmall cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients // J. Clin. Oncol. — 2004. — Vol.22. — 633s.
Review
For citations:
SAKAEVA D.D. Perioperative chemotherapy for non-small-cell lung carcinoma: problems and solutions. Malignant tumours. 2015;(3):18-23. (In Russ.) https://doi.org/10.18027/2224-5057-2015-3-18-23
Views:
963
Email this article 